Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE ...
! It appears that Javascript is disabled on your browser. We're sorry, some parts of the Rightmove website don't work at their best without JavaScript enabled. Please ...